Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
On September 2, C3.ai (NYSE:AI) reported its first quarter of fiscal 2027, and the numbers finally matched the promises. Total revenue reached $52.4 million, subscription revenue made up 94% of that at $49.2 million, and total bookings jumped 73% quarter over quarter. Chief Executive Officer Tom Siebel, three months back in the role, said the […]
The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.
Some companies have raised their dividends through recessions, pandemics, wars, and market crashes without missing a single year, and five of them may be the steadiest income plays a retiree can own right now.
The math behind living off dividends exposes a brutal tradeoff: every percentage point of extra yield you chase to shrink your required capital brings a hidden cost that most income investors never price in before sizing their positions.
Income seekers can't go wrong with these companies.
People familiar with the discussions told Bloomberg that Apollo is working toward a valuation of close to $20 billion for the unit, known as DePuy Synthes.
Alternative asset manager Apollo Global Management Inc. is in discussions to acquire the Johnson & Johnson orthopedics unit that the conglomerate has been looking to separate, according to people familiar with the matter.
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.
Chasing the fattest yield on the screen is a trap most income investors fall into, but a handful of companies have quietly raised their payouts through oil shocks, financial meltdowns, and a global pandemic without skipping a beat. The question is what they all have in common.
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
Cooper Cos. stock has fallen about 25% since Barron’s recommended it, but a low valuation, aggressive share buybacks, and takeover potential bolster the bull case.
Generating $500 a month from dividends sounds straightforward until you see how wildly the required capital swings depending on which stocks you pick and which trade-offs you are willing to accept.
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.
Contact lens maker Cooper Companies just sprung a surprise that no one saw coming. The market had been looking ahead to the potential sale of its women’s health and fertility business CooperSurgical. The stock tumbled more than 15% ahead of the open Thursday, by far the biggest faller in the in premarket trading.
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J. Icotyde could appeal to patients who prefer a pill over an injectable treatment, potentially […]
Wiping out your mortgage with one 401(k) withdrawal feels like a power move, but the tax bracket you land in that year tells a very different story about who actually wins.
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.
Citi just slapped a Buy rating on UiPath with a target nearly 70% above the current price, yet shares keep falling. Here is what the bull and bear camps are fighting over ahead of a high-stakes investor day that could flip the narrative.
Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.